evolocumab
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.
- Target
- Proprotein convertase subtilisin/kexin type 9
- Mechanism
- Subtilisin/kexin type 9 inhibitor
pharma · STEMI
Beijing Luzhu Biopharmaceutical
Beijing Luhe Hospital
Beijing Luzhu Biopharmaceutical drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Beijing, CN HQ
2 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Beijing, CN
- Employees
- 2
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Beijing Luzhu Biopharmaceutical pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Beijing Luzhu Biopharmaceutical drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.